Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1977 Oct;30(1):10–15.

Transfer factor in the attempted treatment of patients with HBsAg-positive chronic liver disease.

S Jain, H C Thomas, S Sherlock
PMCID: PMC1541165  PMID: 606432

Abstract

Six patients with hepatitis B surface antigen-positive (HBsAg-pos) chronic liver disease have been treated with transfer factor (TF) prepared from leucocytes of normal blood donors with no history of hepatitis, and with TF from subjects recently recovered from type B hepatitis. In three patients there were transient elevations of aspartate transaminase (AsT) after 'specific' TF, representing damage or destruction of hepatocytes, and in two of these patients there was coincidental complement consumption, suggesting that TF had stimulated production of antibody. In one other patient there was an increase in E-rosetting lymphocyte (ERL) concentration representing a change in T-lymphocyte reactivity. One of the two patients who had no measured response to TF had a primary liver cell carcinoma and was receiving prednisolone therapy. TF prepared from subjects who have recently recovered from type B hepatitis may have temporarily altered the immunological status of patients with HBsAg-pos chronic liver disease, but it did not have a beneficial therapeutic effect.

Full text

PDF
10

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alpert E., Isselbacher K. J., Schur P. H. The pathogenesis of arthritis associated with viral hepatitis. Complement-component studies. N Engl J Med. 1971 Jul 22;285(4):185–189. doi: 10.1056/NEJM197107222850401. [DOI] [PubMed] [Google Scholar]
  2. Baram P., Yuan L., Mosko M. M. Studies on the transfer of human delayed-type hypersensitivity. I. Partial purification and characterization of two active components. J Immunol. 1966 Sep;97(3):407–420. [PubMed] [Google Scholar]
  3. Drew W. L., Blume M. R., Miner R., Silverberg I., Rosenbaum E. H. Letter: Herpes zoster: transfer factor therapy. Ann Intern Med. 1973 Nov;79(5):747–748. doi: 10.7326/0003-4819-79-5-747. [DOI] [PubMed] [Google Scholar]
  4. Duboczy B. O. Practical significance of booster effect of delayed type of skin test. Am Rev Respir Dis. 1971 May;103(5):719–721. doi: 10.1164/arrd.1971.103.5.719. [DOI] [PubMed] [Google Scholar]
  5. Dudley F. J., Fox R. A., Sherlock S. Cellular immunity and hepatitis-associated, Australia antigen liver disease. Lancet. 1972 Apr 1;1(7753):723–726. doi: 10.1016/s0140-6736(72)90234-6. [DOI] [PubMed] [Google Scholar]
  6. Jondal M., Holm G., Wigzell H. Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med. 1972 Aug 1;136(2):207–215. doi: 10.1084/jem.136.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lawrence H. S. Transfer factor. Adv Immunol. 1969;11:195–266. doi: 10.1016/s0065-2776(08)60480-0. [DOI] [PubMed] [Google Scholar]
  8. Levin A. S., Spitler L. E., Fudenberg H. H. Transfer factor therapy in immune deficiency states. Annu Rev Med. 1973;24:175–208. doi: 10.1146/annurev.me.24.020173.001135. [DOI] [PubMed] [Google Scholar]
  9. Mcintosh R. M., Koss M. N., Gocke K. J. The nature and incidence of cryoproteins in hepatitis B antigen (HbsAg) positive patients. Q J Med. 1976 Jan;45(177):23–38. [PubMed] [Google Scholar]
  12. Roberts I. M., Bernard C. C., Vyas G. N., Mackay I. R. T-cell dependence of immune response to hepatitis B antigen in mice. Nature. 1975 Apr 17;254(5501):606–607. doi: 10.1038/254606a0. [DOI] [PubMed] [Google Scholar]
  13. Rytel M. W., Aaberg T. M., Dee T. H., Heim L. H. Therapy of cytomegalovirus retinitis with transfer factor. Cell Immunol. 1975 Sep;19(1):8–21. doi: 10.1016/0008-8749(75)90287-7. [DOI] [PubMed] [Google Scholar]
  14. Spitler L. E., Levin A. S., Stites D. P., Fudenberg H. H., Pirofsky B., August C. S., Stiehm E. R., Hitzig W. H., Gatti R. A. The Wiskott-Aldrich syndrome. Results of transfer factor therapy. J Clin Invest. 1972 Dec;51(12):3216–3224. doi: 10.1172/JCI107148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tong M. J., Nystrom J. S., Redeker A. G., Marshall G. J. Failure to transfer-factor therapy in chronic active type B hepatitis. N Engl J Med. 1976 Jul 22;295(4):209–211. doi: 10.1056/NEJM197607222950408. [DOI] [PubMed] [Google Scholar]
  16. Tong M. J., Wallace A. M., Peters R. L., Reynolds T. B. Lymphocyte stimulation in hepatitis B infections. N Engl J Med. 1975 Aug 14;293(7):318–322. doi: 10.1056/NEJM197508142930702. [DOI] [PubMed] [Google Scholar]
  17. Wands J. R., Mann E., Alpert E., Isselbacher K. J. The pathogenesis of arthritis associated with acute hepatitis-B surface antigen-positive hepatitis. Complement activation and characterization of circulating immune complexes. J Clin Invest. 1975 May;55(5):930–936. doi: 10.1172/JCI108022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wybran J., Levin A. S., Spitler L. E., Fudenberg H. H. Rosette-forming cells, immunologic deficiency diseases and transfer factor. N Engl J Med. 1973 Apr 5;288(14):710–713. doi: 10.1056/NEJM197304052881405. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES